Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids

被引:11
作者
Oreja-Guevara, Celia [1 ]
机构
[1] Hosp Clin San Carlos, Unidad Esclerosis Multiple, Serv Neurol, IdISSC, E-28040 Madrid, Spain
关键词
Cannabidiol; Cannabinoids; Delta-9-tetrahydrocannabinol; Endocannabinoid system; Multiple sclerosis; Pain; Spasticity; DOUBLE-BLIND; PREVALENCE; PLACEBO; SYMPTOMS; ENDOCANNABINOIDS; MANAGEMENT; SATIVEX(R); MEDICINE; TRIAL; SPAIN;
D O I
10.33588/rn.5507.2012362
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Spasticity remains a prevalent symptom in multiple sclerosis, with a significant associated disability and quality of life impairment. A significant improvement in therapy aimed at reducing multiple sclerosis relapses and modifying its course has been achieved in recent years. Both general and specific traditional treatments have, however, major limitations. Thus, its use in real practice is lower than expected. Cannabinoids provide a new way for therapy. A delta-9-tetrahydrocannabinol plus cannabidiol (1:1) association, administered through an oromucosal route, has been approved in several countries including Spain; it causes a specific effect on CB1 and CB2 receptors, with traditional psychotropic cannabis actions being minimized. Randomized, placebo-controlled trials, as well as longer-term open-label extensions, have shown a clear-cut efficacy to reduce spasticity and their associated symptoms in those patients refractory to other therapies, with a good tolerability/safety profile. No tolerance, abuse or addictive issues have been found. New studies will be needed to find out potential new cannabinoid-related therapies.
引用
收藏
页码:421 / 430
页数:10
相关论文
共 46 条
[1]   Prevalence and incidence of multiple sclerosis in Las Palmas, Canary Islands, Spain [J].
Aladro, Y ;
Alemany, MJ ;
Pérez-Vieitez, MC ;
Amela, R ;
Conde, M ;
Reyes, MP ;
Alamo, F ;
Angel-Moreno, A .
NEUROEPIDEMIOLOGY, 2005, 24 (1-2) :70-75
[2]   A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis [J].
Anwar, Khalid ;
Barnes, M. P. .
NEUROREHABILITATION, 2009, 24 (04) :333-340
[3]   Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis: A Double-Blind, Placebo Controlled, Crossover Study [J].
Aragona, Massimiliano ;
Onesti, Emanuela ;
Tomassini, Valentina ;
Conte, Antonella ;
Gupta, Shiva ;
Gilio, Francesca ;
Pantano, Patrizia ;
Pozzilli, Carlo ;
Inghilleri, Maurizio .
CLINICAL NEUROPHARMACOLOGY, 2009, 32 (01) :41-47
[4]  
Arroyo R, 2011, EXPERT REV PHARM OUT, V11, P205, DOI [10.1586/erp.11.6, 10.1586/ERP.11.6]
[5]   Evidence for novel cannabinoid receptors [J].
Begg, M ;
Pacher, P ;
Bátkai, S ;
Osei-Hyiaman, D ;
Offertáler, L ;
Mo, FM ;
Liu, H ;
Kunos, G .
PHARMACOLOGY & THERAPEUTICS, 2005, 106 (02) :133-145
[6]   Cannabinoid Receptors and Endocannabinoids: Role in Neuroinflammatory and Neurodegenerative Disorders [J].
Bisogno, Tiziana ;
Di Marzo, Vincenzo .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2010, 9 (05) :564-573
[7]   Cannabis use in patients with multiple sclerosis [J].
Chong, M. S. ;
Wolff, K. ;
Wise, K. ;
Tanton, C. ;
Winstock, A. ;
Silber, E. .
MULTIPLE SCLEROSIS JOURNAL, 2006, 12 (05) :646-651
[8]   Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis [J].
Collin, C. ;
Davies, P. ;
Mutiboko, I. K. ;
Ratcliffe, S. .
EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 (03) :290-296
[9]   A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis [J].
Collin, C. ;
Ehler, E. ;
Waberzinek, G. ;
Alsindi, Z. ;
Davies, P. ;
Powell, K. ;
Notcutt, W. ;
O'Leary, C. ;
Ratcliffe, S. ;
Novakova, I. ;
Zapletalova, O. ;
Pikova, J. ;
Ambler, Z. .
NEUROLOGICAL RESEARCH, 2010, 32 (05) :451-459
[10]  
Collin C, 2007, MULT SCLER, V13